Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Multimedia Patient Education

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Video
Behavioral: Questionnaires

First Posted Date: 2010-08-19

Last Posted Date: 2013-02-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT01184534

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Drug: Everolimus
Drug: Sunitinib

First Posted Date: 2010-08-19

Last Posted Date: 2021-04-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 73

Registration Number: NCT01185366

Locations: 🇺🇸
Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Huntsman Cancer Institute - University of Utah, Salt Lake City, Utah, United States

and more 1 locations

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Lenalidomide
Drug: Bevacizumab
Drug: Sorafenib
Drug: Temsirolimus
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-fluorouracil

First Posted Date: 2010-08-17

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT01183663

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib

First Posted Date: 2010-08-12

Last Posted Date: 2022-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT01180959

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Symptom Inventory for Gastrointestinal Stromal Tumors

Conditions: Gastrointestinal Stromal Tumors

Interventions: Behavioral: Questionnaires
Behavioral: MDASI-GIST Questionnaire
Behavioral: Interview

First Posted Date: 2010-08-10

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 187

Registration Number: NCT01178307

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trientine and Carboplatin in Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Trientine MTD
Drug: Trientine
Drug: Carboplatin MTD
Drug: Carboplatin
Other: PK Testing

First Posted Date: 2010-08-09

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT01178112

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Not Applicable

Completed

Conditions: Stage III Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Unresectable Hepatocellular Carcinoma
Stage IIIA Hepatocellular Carcinoma AJCC v8

Interventions: Radiation: Yttrium Y 90 Glass Microspheres

First Posted Date: 2010-08-06

Last Posted Date: 2022-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 299

Registration Number: NCT01176604

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Phase 2

Terminated

Conditions: Myeloma

Interventions: Biological: KLH Vaccine
Biological: KLH-id Vaccine
Drug: GM-CSF
Procedure: Donor Lymphocyte Infusion (DLI)
Procedure: Apheresis

First Posted Date: 2010-08-03

Last Posted Date: 2018-06-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01174082

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.

Phase 2

Completed

Conditions: Oropharynx Cancer

Interventions: Drug: Placebo
Drug: Minocycline

First Posted Date: 2010-08-02

Last Posted Date: 2021-08-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01173692

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

Not Applicable

Terminated

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Placebo
Drug: Armodafinil

First Posted Date: 2010-07-26

Last Posted Date: 2015-12-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01169753

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy